Christine Joshua, DPM
Foot & Ankle Surgery · Amarillo, TXNPI 1003468398
Payments from drug & device makers
What this record shows
This record is dominated by education: $7,177 of the $8,945 with a category attached, or 80.2%. Pylant Medical accounts for 76.6% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $3,256 and has fallen 95.1% since, to $160 in 2025.
Across 48 payments — averaging $186.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pylant Medical$7K
- Medical Device Business Services, Inc.$438
- Stryker$346
- Integra Lifesciences Corporation$302
- Smith+Nephew$196
- Paragon 28, Inc.$165
- plus $645 from 14 others
What the payments were for
- Food & beverage$1,76820%
- Education$7,17780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pylant Medical | 7 | $6,852 |
| Medical Device Business Services, Inc. | 2 | $438 |
| Stryker(2 entities) | 6 | $346 |
| Integra Lifesciences Corporation | 3 | $302 |
| Smith+Nephew | 5 | $196 |
| Paragon 28, Inc. | 2 | $165 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $165 |
| Melinta Therapeutics, LLC | 1 | $116 |
| Arthrex | 1 | $89 |
| Orthofix Medical, Inc. | 8 | $57 |
| Johnson & Johnson | 2 | $37 |
| Globus Medical | 1 | $37 |
| Bioventus LLC | 2 | $34 |
| Rattan And Associates | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Organogenesis Inc. | 1 | $18 |
| Kerecis Limited | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Zimmer Biomet | 1 | $12 |
| Advanced Oxygen Therapy Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CYTAL$517
- Product Portfolio$145
- AUGMENT INJECTABLE$135
- Kimyrsa$116
How this compares
$8,945 in reported general payments places this provider in the 70th percentile of 684 foot & ankle surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ciclopirox | 12 | $396 |
| Doxycycline Hyclate | 28 | $177 |
| Methylprednisolone | 11 | $96 |
| Cephalexin | 22 | $71 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Amarillo
- William McGarveyKaty$3.5M
- Eugene CurryDallas$3.1M
- Graham HamiltonEdinburg$2.1M
- Mark DaltonAustin$1.9M
- Kevin VarnerHouston$1.1M
- Paul KimDallas$928K
- Sherman NaglerHouston$602K
- John EarlyDallas$553K
- Michael DowneySouthlake$475K
- Abdul NurudeenHouston$404K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.